Sugi Predict

Sugi Predict / Targets / PFDN1

PFDN1

Prefoldin subunit 1 · O60925 · PFDN1 on Sugi Atlas →

0 patent compounds predicted against PFDN1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PFDN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Ketamine Treatment Effects on Synaptic Plasticity in Depression PHASE4COMPLETED
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
C-Protein in Fatigue and Aging nanRECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Identification of New FTLD Genes nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Transcranial Magnetic Stimulation (TMS) Studies of Dystonia nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Acute Passive Heating in Healthy Older Adults nanCOMPLETED
Familial Partial Lipodystrophy Study nanCOMPLETED
Gene Analysis of Parkinson's Disease nanCOMPLETED
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome nanCOMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure? nanRECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PFDN1 binder may also engage these)

ProteinNameSimilarity
Q3SZE2 — 1.000 Q3SZE2 →
Q5RAM7 — 1.000 Q5RAM7 →
Q9CWM4 — 0.997 Q9CWM4 →
Q5D016 — 0.944 Q5D016 →
A1A4P5 — 0.898 A1A4P5 →
P80585 — 0.897 P80585 →
B0BN18 — 0.895 B0BN18 →
PFDN2 Prefoldin subunit 2 0.895 landscape →
Q6PEC1 — 0.895 Q6PEC1 →
O70591 — 0.895 O70591 →
Q4SPU8 — 0.893 Q4SPU8 →
Q9BWT6 — 0.892 Q9BWT6 →
Q32L19 — 0.891 Q32L19 →
GPS1 COP9 signalosome complex subunit 1 0.886 landscape →
Q8K396 — 0.886 Q8K396 →
Q6NRT5 — 0.883 Q6NRT5 →
TBCA Tubulin-specific chaperone A 0.883 landscape →
Q8TAG9 — 0.882 Q8TAG9 →
Q3T075 — 0.882 Q3T075 →
Q6I9Y2 — 0.881 Q6I9Y2 →
E2R766 — 0.881 E2R766 →
Q5ZKV9 — 0.881 Q5ZKV9 →
Q5RBL6 — 0.881 Q5RBL6 →
F1LSG8 — 0.880 F1LSG8 →
Q7TMY4 — 0.880 Q7TMY4 →
Q8CI71 — 0.880 Q8CI71 →
Q61187 — 0.880 Q61187 →
P48428 — 0.879 P48428 →
P48427 — 0.879 P48427 →
A6H5Z3 — 0.879 A6H5Z3 →